Personal tools

Coexpression cluster:C244: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 3: Line 3:
|gostat_on_coexpression_clusters=GO:0042602!flavin reductase activity!0.0151883084852404!645$GO:0004074!biliverdin reductase activity!0.0151883084852404!645$GO:0001892!embryonic placenta development!0.0189828707762266!1051$GO:0019863!IgE binding!0.0189828707762266!3958$GO:0045408!regulation of interleukin-6 biosynthetic process!0.0220784317266505!1051$GO:0042226!interleukin-6 biosynthetic process!0.0220784317266505!1051$GO:0032635!interleukin-6 production!0.0220784317266505!1051$GO:0001890!placenta development!0.0220784317266505!1051$GO:0045444!fat cell differentiation!0.0220784317266505!1051$GO:0016628!oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor!0.0220784317266505!645$GO:0019865!immunoglobulin binding!0.0220784317266505!3958$GO:0005737!cytoplasm!0.0252768643803778!54625;3958;645;1051$GO:0006953!acute-phase response!0.0368338048269068!1051$GO:0016646!oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor!0.0368338048269068!645$GO:0003950!NAD+ ADP-ribosyltransferase activity!0.0384159270903756!54625$GO:0001701!in utero embryonic development!0.0463558843129863!1051$GO:0016645!oxidoreductase activity, acting on the CH-NH group of donors!0.0463558843129863!645
|gostat_on_coexpression_clusters=GO:0042602!flavin reductase activity!0.0151883084852404!645$GO:0004074!biliverdin reductase activity!0.0151883084852404!645$GO:0001892!embryonic placenta development!0.0189828707762266!1051$GO:0019863!IgE binding!0.0189828707762266!3958$GO:0045408!regulation of interleukin-6 biosynthetic process!0.0220784317266505!1051$GO:0042226!interleukin-6 biosynthetic process!0.0220784317266505!1051$GO:0032635!interleukin-6 production!0.0220784317266505!1051$GO:0001890!placenta development!0.0220784317266505!1051$GO:0045444!fat cell differentiation!0.0220784317266505!1051$GO:0016628!oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor!0.0220784317266505!645$GO:0019865!immunoglobulin binding!0.0220784317266505!3958$GO:0005737!cytoplasm!0.0252768643803778!54625;3958;645;1051$GO:0006953!acute-phase response!0.0368338048269068!1051$GO:0016646!oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor!0.0368338048269068!645$GO:0003950!NAD+ ADP-ribosyltransferase activity!0.0384159270903756!54625$GO:0001701!in utero embryonic development!0.0463558843129863!1051$GO:0016645!oxidoreductase activity, acting on the CH-NH group of donors!0.0463558843129863!645
|id=C244
|id=C244
|ontology_enrichment_celltype=CL:0002032!3.01e-31!165;CL:0000837!3.01e-31!165;CL:0000738!3.58e-31!140;CL:0000037!3.88e-31!172;CL:0000566!3.88e-31!172;CL:0000766!1.08e-30!76;CL:0000763!3.60e-29!112;CL:0000049!3.60e-29!112;CL:0000988!5.10e-28!182;CL:0002009!1.22e-26!65;CL:0002087!1.72e-26!119;CL:0000557!2.29e-26!71;CL:0002031!3.57e-26!124;CL:0002194!1.44e-25!63;CL:0000576!1.44e-25!63;CL:0000040!1.44e-25!63;CL:0000559!1.44e-25!63;CL:0000839!2.48e-25!70;CL:0002057!1.91e-22!42;CL:0000860!1.37e-21!45;CL:0000134!4.16e-07!358
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0002390!1.01e-29!102;UBERON:0003061!1.01e-29!102;UBERON:0002193!1.76e-25!112;UBERON:0002371!3.61e-23!80;UBERON:0001474!2.52e-21!86;UBERON:0002405!5.99e-17!115;UBERON:0004765!4.17e-16!101;UBERON:0001434!4.17e-16!101;UBERON:0000178!6.17e-08!15;UBERON:0000179!6.17e-08!15;UBERON:0000463!6.17e-08!15
}}
}}

Revision as of 14:24, 21 May 2012


Full id: C244_CD14_Monocytederived_Hepatocyte_heart_Neutrophils_acute_Macrophage



Phase1 CAGE Peaks

Hg19::chr10:81025241..81025245,+p@chr10:81025241..81025245
+
Hg19::chr10:81111074..81111077,+p@chr10:81111074..81111077
+
Hg19::chr11:104815548..104815551,-p@chr11:104815548..104815551
-
Hg19::chr12:56046384..56046387,+p@chr12:56046384..56046387
+
Hg19::chr12:89431933..89431936,-p@chr12:89431933..89431936
-
Hg19::chr14:100828867..100828870,-p@chr14:100828867..100828870
-
Hg19::chr14:55603238..55603250,+p15@LGALS3
Hg19::chr16:21623958..21623973,+p@chr16:21623958..21623973
+
Hg19::chr16:31360617..31360620,-p@chr16:31360617..31360620
-
Hg19::chr16:31381019..31381027,+p@chr16:31381019..31381027
+
Hg19::chr16:31926633..31926654,+p@chr16:31926633..31926654
+
Hg19::chr16:50706590..50706610,-p@chr16:50706590..50706610
-
Hg19::chr17:54976102..54976122,-p@chr17:54976102..54976122
-
Hg19::chr17:75352671..75352704,+p@chr17:75352671..75352704
+
Hg19::chr19:40972117..40972122,-p4@BLVRB
Hg19::chr19:4569647..4569651,+p@chr19:4569647..4569651
+
Hg19::chr19:6663476..6663487,-p8@AK026704
Hg19::chr19:6663488..6663497,-p5@AK026704
Hg19::chr19:6663518..6663558,-p2@AK026704
Hg19::chr19:6663572..6663662,-p1@AK026704
Hg19::chr19:6663833..6663841,-p6@AK026704
Hg19::chr19:6663876..6663885,-p7@AK026704
Hg19::chr1:145038845..145038849,-p@chr1:145038845..145038849
-
Hg19::chr1:154435643..154435648,+p@chr1:154435643..154435648
+
Hg19::chr1:159787777..159787780,-p@chr1:159787777..159787780
-
Hg19::chr1:25362175..25362187,+p@chr1:25362175..25362187
+
Hg19::chr1:25362249..25362302,+p@chr1:25362249..25362302
+
Hg19::chr1:25362605..25362625,+p@chr1:25362605..25362625
+
Hg19::chr20:39690091..39690102,+p@chr20:39690091..39690102
+
Hg19::chr20:48809000..48809053,+p12@CEBPB
Hg19::chr21:30613305..30613309,+p@chr21:30613305..30613309
+
Hg19::chr22:36632299..36632310,-p@chr22:36632299..36632310
-
Hg19::chr2:240202309..240202321,+p@chr2:240202309..240202321
+
Hg19::chr2:240202391..240202405,+p@chr2:240202391..240202405
+
Hg19::chr2:240202435..240202445,+p@chr2:240202435..240202445
+
Hg19::chr2:240202757..240202766,+p@chr2:240202757..240202766
+
Hg19::chr2:87781799..87781811,+p@chr2:87781799..87781811
+
Hg19::chr2:87781831..87781841,+p@chr2:87781831..87781841
+
Hg19::chr3:122399875..122399886,+p7@PARP14
Hg19::chr3:122444648..122444658,+p@chr3:122444648..122444658
+
Hg19::chr3:15483499..15483511,+p@chr3:15483499..15483511
+
Hg19::chr3:196044455..196044479,-p@chr3:196044455..196044479
-
Hg19::chr5:55160032..55160047,+p@chr5:55160032..55160047
+
Hg19::chr5:55160483..55160494,+p@chr5:55160483..55160494
+
Hg19::chr6:74410846..74410849,+p@chr6:74410846..74410849
+
Hg19::chr6:74492716..74492719,+p@chr6:74492716..74492719
+
Hg19::chr6:74512050..74512056,+p@chr6:74512050..74512056
+
Hg19::chr7:130575788..130575792,-p@chr7:130575788..130575792
-
Hg19::chr7:47513678..47513702,+p@chr7:47513678..47513702
+
Hg19::chr7:47514268..47514279,+p@chr7:47514268..47514279
+
Hg19::chr8:20094845..20094867,+p@chr8:20094845..20094867
+
Hg19::chr8:24250424..24250429,+p@chr8:24250424..24250429
+
Hg19::chr8:62606823..62606835,-p@chr8:62606823..62606835
-
Hg19::chr9:90343853..90343856,+p@chr9:90343853..90343856
+
Hg19::chrX:118129290..118129323,+p@chrX:118129290..118129323
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0042602flavin reductase activity0.0151883084852404
GO:0004074biliverdin reductase activity0.0151883084852404
GO:0001892embryonic placenta development0.0189828707762266
GO:0019863IgE binding0.0189828707762266
GO:0045408regulation of interleukin-6 biosynthetic process0.0220784317266505
GO:0042226interleukin-6 biosynthetic process0.0220784317266505
GO:0032635interleukin-6 production0.0220784317266505
GO:0001890placenta development0.0220784317266505
GO:0045444fat cell differentiation0.0220784317266505
GO:0016628oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor0.0220784317266505
GO:0019865immunoglobulin binding0.0220784317266505
GO:0005737cytoplasm0.0252768643803778
GO:0006953acute-phase response0.0368338048269068
GO:0016646oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor0.0368338048269068
GO:0003950NAD+ ADP-ribosyltransferase activity0.0384159270903756
GO:0001701in utero embryonic development0.0463558843129863
GO:0016645oxidoreductase activity, acting on the CH-NH group of donors0.0463558843129863



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
hematopoietic system1.01e-29102
blood island1.01e-29102
hemolymphoid system1.76e-25112
bone marrow3.61e-2380
bone element2.52e-2186
immune system5.99e-17115
skeletal element4.17e-16101
skeletal system4.17e-16101
blood6.17e-0815
haemolymphatic fluid6.17e-0815
organism substance6.17e-0815


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.